Anti‐SARS‐CoV‐2 Spike Antibodies are Stable in Convalescent Plasma when Stored at 4° Celsius for at Least 6 Weeks
18 Aug, 2020As nations around the world continue to address the public health crisis of Coronavirus Disease 2019 (COVID19), the global medical and scientific communities continue to search for and develop therapeutic strategies for patients. To date, remdesivir presents one such option and can shorten the duration of hospitalization in patients with severe disease. Convalescent plasma (CP) has presented another option, with its use and safety supported by numerous case series and retrospective studies. While its degree of effectiveness has been variable, there is general agreement that it acts as a supportive adjunctive therapy in patients with moderate to severe disease.
For reading full text click the link.